首页> 外文期刊>Journal of Electrophoresis >Searching for new biomarkers of bladder cancer based on proteomic analysis
【24h】

Searching for new biomarkers of bladder cancer based on proteomic analysis

机译:基于蛋白质组学分析寻找膀胱癌的新生物标志物

获取原文
获取原文并翻译 | 示例
       

摘要

Urine cytology is the gold standard for detection of bladder cancer. However, it has poor sensitivity, and currently several diagnostic markers have high false-positive rates. One of the problems with bladder cancer is high locoregional recurrence after surgery. Therefore new diagnostic markers of bladder cancer are needed. We have conducted a comprehensive study of high molecular mass (HMM) protein expression in bladder cancer tissue by means of agarose two-dimensional gel electrophoresis (agarose 2-DE) followed by the analysis of liquid chromatography tandem mass spectroscopy. We successfully identified 53 proteins from cancer tissue and 33 proteins from normal mucosa in the HMM area of the 2DE gel, and they were classified as proteins of transcription, translation or the cytoskeleton. Among them, eight differentially regulated proteins were selected as new marker candidates, and we performed experiments to validate their use as diagnostic markers. The results of Western blotting showed that these proteins except for a spectrin were significantly upregulated in bladder cancer tissue, and one of them, structural maintenance of chromosomes protein 3 (SMC3), was specifically detected in urine samples from bladder cancer patients. On the other hand, the results of Immunohistochemistry showed that expression of neuroblast differentiation-associated protein AHNAK (AHNAK) was significantly increased and that of plectin-1 was significantly decreased in the bladder cancer specimens compared with normal bladder mucosa specimens. However, no significant difference was observed in other proteins. These results suggest that AHNAK and Plectin-1 would be the potential markers for urine cytology and SMC3 is possible to be that for diagnosis marker for urinalysis.
机译:尿液细胞学检查是检测膀胱癌的金标准。但是,它的敏感性很差,目前,几种诊断标记物的假阳性率很高。膀胱癌的问题之一是手术后局部复发率高。因此,需要新的膀胱癌诊断标志物。我们通过琼脂糖二维凝胶电泳(琼脂糖2-DE)对液相色谱串联质谱法进行了分析,对膀胱癌组织中高分子量(HMM)蛋白的表达进行了全面研究。我们成功地从2DE凝胶HMM区域的癌组织中鉴定出53种蛋白质,并从正常粘膜中鉴定出33种蛋白质,它们被分类为转录,翻译或细胞骨架蛋白。其中,选择了8个差异调节蛋白作为新的候选标记,我们进行了实验以验证其作为诊断标记的用途。蛋白质印迹的结果表明,除了血红蛋白外,这些蛋白在膀胱癌组织中显着上调,其中之一是在膀胱癌患者的尿液样本中特异性检测到了染色体蛋白3(SMC3)的结构维持。另一方面,免疫组织化学结果显示,与正常膀胱粘膜标本相比,膀胱癌标本中神经母细胞分化相关蛋白AHNAK(AHNAK)的表达显着增加,而plectin-1的表达显着降低。但是,在其他蛋白质中未观察到显着差异。这些结果表明,AHNAK和Plectin-1是尿液细胞学的潜在标志物,而SMC3可能是尿液分析的诊断标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号